What do systematic reviews say?

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

The review found no eligible studies for this question.

• Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser therapy vs no laser therapy

The review found no eligible studies for this question.

• Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: anti‐pseudomonal antibiotics vs placebo

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 245 participants
  Low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  Low

Intervention not reported

• Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Moderate

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 294 participants
  Moderate

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 374 participants
  Low

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Summary of findings: aztreonam lysine for inhalation vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 268 participants
  Moderate